Following on from information provided to NICE by the company in May 2017, the appraisal of Leukaemia (acute myeloid, relapsed, refractory) - vosaroxin was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 746
Email enquiries
If you have any queries please email scheduling@nice.org.uk
- External Assessment Group:
- Health Economics Research Unit and Health Services Research Unit, University of Aberdeen
Stakeholders
- Companies sponsors
- Sunesis
- Others
- Department of Health
- NHS England
- NHS Somerset CCG
- NHS South Eastern Hampshire CCG
- Welsh Government
- Patient carer groups
- African Caribbean Leukaemia Trust
- Anthony Nolan
- Black Health Agency
- Cancer Black Care
- Cancer Equality
- Cancer52
- Delete Blood Cancer
- Equalities National Council
- HAWC
- Helen Rollason Cancer Charity
- Independent Cancer Patients Voice
- Leukaemia Cancer Society
- Leukaemia CARE
- Macmillan Cancer Support
- Maggie’s Centres
- Marie Curie Cancer Care
- Muslim Council of Britain
- South Asian Health Foundation
- Specialised Healthcare Alliance
- Tenovus Cancer Care
- UK Chronic Lymphocytic Leukaemia Forum
- Professional groups
- Association of Cancer Physicians
- British Blood Transfusion Society
- British Committee for Standards in Haematology
- British Geriatrics Society
- British Institute of Radiology
- British Psychosocial Oncology Society
- British Society for Haematology
- Cancer Research UK
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians
- Royal College of Radiologists
- Royal Pharmaceutical Society
- Royal Society of Medicine
- Society and College of Radiography
- UK Clinical Pharmacy Association
- UK Health Forum
- UK Oncology Nursing Society
- Associated public health groups
- Public Health England
- Public Health Wales
- Comparator companies
- Accord (cytarabine, filgrastim )
- Actavis (fludarabine)
- Amgen (filgrastim)
- Hospira UK (cytarabine, fludarabine, filgrastim )
- Napp Pharmaceuticals (cytarabine)
- Pfizer (cytarabine, idarubicin)
- Sandoz (fludarabine, filgrastim)
- Teva (fludarabine)
- General commentators
- Allied Health Professionals Federation
- Board of Community Health Councils in Wales
- British National Formulary
- Care Quality Commission
- Department of Health, Social Services and Public Safety for Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- National Association of Primary Care
- National Pharmacy Association
- NHS Alliance
- NHS Blood and Transplant
- NHS Commercial Medicines Unit
- NHS Confederation
- Scottish Medicines Consortium
- Relevant research groups
- Bloodwise
- Cochrane Haematological Malignancies Group
- Institute of Cancer Research
- Leuka
- Leukaemia Busters
- MRC Clinical Trials Unit
- National Cancer Research Institute
- National Cancer Research Network
- National Institute for Health Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 16 November 2022 | Discontinued. Following on from information provided to NICE by the company in May 2017, the appraisal of Leukaemia (acute myeloid, relapsed, refractory) - vosaroxin was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 19 April 2017 | Suspended. The Department of Health has asked NICE to conduct a Single Technology Appraisal of vosaroxin within its marketing authorisation for treating relapsed or refractory acute myeloid leukaemia. Following on from advice received from the company, NICE has decided to currently suspend this appraisal on its work programme. As this appraisal has been referred we will continue to monitor any development and will update interested parties when the situation changes. |
| 14 February 2017 | Invitation to participate |
| 09 November 2016 | Sunesis was unable to make a submission to NICE ahead of the marketing authorisation for Vosaroxin based on resource constraints and intends to follow up with a full submission in a timely manner. NICE therefore rescheduled this appraisal. |
| 02 June 2016 | Draft scope documents |
| 13 May 2016 | Referral |
For further information on our processes and methods, please see our CHTE processes and methods manual